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Practice effects in a longitudinal, multi-center
Alzheimer’s disease prevention clinical trial
Erin L Abner1, Brandon C Dennis1,2, Melissa J Mathews1,2, Marta S Mendiondo1,3, Allison Caban-Holt1,5,
Richard J Kryscio1,3,4, Frederick A Schmitt1,2,5,6,8* for the PREADViSE Investigators John J Crowley7 and for the
SELECT Investigators
Abstract
Background: Practice effects are a known threat to reliability and validity in clinical trials. Few studies have
investigated the potential influence of practice on repeated screening measures in longitudinal clinical trials with a
focus on dementia prevention. The current study investigates whether practice effects exist on a screening measure
commonly used in aging research, the Memory Impairment Screen (MIS).
Methods: The PREADViSE trial is a clinical intervention study evaluating the efficacy of vitamin E and selenium for
Alzheimer’s disease prevention. Participants are screened annually for incident dementia with the MIS. Participants
with baseline and three consecutive follow-ups who made less than a perfect score at one or more assessments
were included in the current analyses (N=1,803). An additional subset of participants with four consecutive
assessments but who received the same version of the MIS at baseline and first follow-up (N=301) was also
assessed to determine the effects of alternate forms on mitigating practice. We hypothesized that despite efforts to
mitigate practice effects with alternate versions, MIS scores would improve with repeated screening. Linear mixed
models were used to estimate mean MIS scores over time.
Results: Among men with four visits and alternating MIS versions, although there is little evidence of a significant
practice effect at the first follow-up, mean scores clearly improve at the second and third follow-ups for all but the
oldest participants. Unlike those who received alternate versions, men given the same version at first follow-up
show significant practice effects.
Conclusion: While increases in the overall means were small, they represent a significant number of men whose
scores improved with repeated testing. Such improvements could bias case ascertainment if not taken into
account.
Keywords: Practice effects, Clinical trials, Alzheimer’s disease, Neuropsychological assessment
Background
Serial cognitive assessment is used in clinical practice,
clinical trials, and longitudinal studies of aging and de-
mentia to track cognitive fluctuations over time and to
identify clinically significant declines in performance sug-
gestive of mild cognitive impairment (MCI) or dementia.
Screening measures with specific cut-points reflecting
probable cognitive impairment are also frequently used as
brief, first-line measures of gross cognitive functioning in
both clinical and research settings. For example, patients
performing below the cut-point on a screening measure
may be referred for more extensive diagnostic evaluation.
Research participants may be screened into or out of stud-
ies based upon whether their performance lies above or
below the cut-point of the measure. When cognitive
instruments are used repeatedly, it is imperative to know
not only the sensitivity, specificity, positive predictive
value, and negative predictive value of the instruments,
but also their behavior over time.
Practice effects (PE) represent one aspect of that be-
havior. PE are distinct from random fluctuations in per-
formance and refer to bias due to familiarity with test
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items and procedures when a test is retaken [1]. Longi-
tudinal studies of cognitive aging are highly dependent
on repeated testing with neuropsychological measures.
For example, dementia prevention trials such as the
Alzheimer’s Disease Anti-inflammatory Prevention Trial
(ADAPT) [2], Gingko Evaluation of Memory Study
(GEMS) [3], and the Prevention of Alzheimer’s Disease
by Vitamin E and Selenium (PREADViSE) trial [4] rely
heavily on repeated cognitive screening measures and
standardized cognitive batteries for case ascertainment
and tracking response to treatment.
Most studies demonstrating practice effects have
involved test-retest paradigms over short time intervals
[5-9] or have been conducted primarily with impaired
populations [10-12]. Nonetheless, repeated testing effects
have been well documented [13-17], and performance
variability has been demonstrated to be influenced by age
[18-21], fluid intelligence [21], clinical population [10,22],
retest interval [9,12,23,24], and the test or neurocognitive
domain assessed [25,26]. Knowledge of the effects of
repeated presentation is essential for interpretation of
results. For example, PE can potentially alter the mea-
sure’s sensitivity to cognitive change and have been found
to account for between 31 and 83% of the variance in
follow-up test scores [26]. Further, PE could influence de-
mentia detection in prevention trials when screening mea-
sures are used, especially given known PE, even for
participants with Alzheimer’s disease (AD), on measures
such as the Mini-Mental State Exam [12].
Furthermore, PE may persist over long periods of time.
In the UK, Rabbit and colleagues [20] examined PE over
a 17-year period in 5,899 participants, ages 49 to 92.
Similar to other studies, they found the greatest gain in
performance between the first and second presentation
but observed gains due to practice on intelligence tests
over intervals of several years. In a separate sample
studied over a 20-year period, the same authors again
observed significant PE, even with time intervals of up
to four years [21]. Given this finding, it is also likely that
PE may affect whether one performs above or below a
single cut-point and thus influence case ascertainment
in longitudinal clinical trials.
In the present study, we sought to examine PE on the
Memory Impairment Screen (MIS) over four annual
administrations. Brief memory screening instruments are
often used in clinical practice and research to identify
those patients who might benefit from a more extensive
clinical assessment, and whether specific individuals
should be included in a research study. Some studies,
such as the PREADViSE trial, rely on dementia screen-
ing measures to determine whether a participant should
be evaluated with more in-depth cognitive assessment.
More specifically, if performance on screening measures
is influenced by PE, participants who may be cognitively
impaired or demented will be adjudicated as cognitively
normal and thus misclassified or potentially lost to fol-
low-up. Given previous data on short-term and long-
term PE, we hypothesized that despite efforts to mitigate
PE through alternate test versions, MIS scores would
improve over time.
Methods
Participants
For details on recruitment and design of the National
Institutes of Health (NIH) National Institute on Aging-
sponsored PREADViSE trial, please see Kryscio et al. [4].
Briefly, the primary aim is to determine the effectiveness
of the antioxidant supplements vitamin E and selenium
in preventing the onset of AD. The PREADViSE trial
recruited a subsample (n = 7,547) of participants age 62
and over (age 60 if of African-American descent) from
the NIH National Cancer Institute-sponsored Selenium
and Vitamin E Cancer Prevention Trial (SELECT) from
130 participating clinical sites in the US, Canada, and
Puerto Rico. Men enrolled in both the SELECT prostate
cancer study [27] and the PREADViSE trial, who com-
pleted baseline and three consecutive follow-up assess-
ments, and obtained less than a perfect score at one or
more assessments (n = 1,803) were included in the
current analyses. Men with four consecutive assessments
were selected to provide adequate follow-up to examine
potential PE, and men with perfect scores at all assess-
ments were excluded because their scores could not im-
prove. However, these men (n = 1,291) were included in
a sensitivity analysis.
Despite bi-annual training sessions on the screening
protocol with the site clinical research assistants (CRAs)
[28], there were administration errors that resulted in
some men receiving the same MIS version at consecutive
visits. Thus, an additional subset of men who received the
same version of the test protocol (due to CRA error) at
baseline and first follow-up and obtained less than a per-
fect score at any of the four assessments (n = 301) were
also analyzed to determine the effectiveness of alternate
forms in mitigating PE.
This study was approved by the University of Kentucky
Institutional Review Board as well as the Institutional Re-
view Boards at all participating centers.
Clinical evaluation
The study employs a two-tier cognitive screening pro-
cedure for identification of memory impairment and
dementia. The first consists of the MIS [29], which is
administered at each annual visit. Participants who score
below the predetermined cut-point on the MIS undergo
a more extensive cognitive evaluation and medical work-
up [28]. The MIS was chosen for its brevity (under five
minutes) and ease of administration with minimal
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training by CRAs, who were well-versed in cancer re-
search but had no other training or experience in
administering cognitive tests. To minimize PE, the alter-
nate form of the MIS [29] was also included in the
protocol for subsequent annual assessments. At each
follow-up screen, the participant received the version
not administered to him the previous year. During MIS
administration, the participant is shown four written
words and verbally given a category cue for each; after a
2-minute interval filled with a non-memory-based dis-
traction task, the participant is asked to recall the words
(free recall). Category cues may be given as needed to
stimulate recall (cued recall). Two points are awarded
for each correct free recall word, and one point is scored
for each correct word following category cue. MIS total
scores range from 0 to 8 points with 8 points indicating
a perfect score, and a standard cut-point, recommended
by Buschke and the test authors [29] is a score of 4. MIS
screening began in May 2002 and will continue through
January 2013. The cut-point was raised to 5 in January
2009 to capture participants potentially functioning in
the MCI range.
Statistical methods
Linear mixed models (LMM) were used to test the hy-
pothesis that MIS scores improve over time due to PE.
Random intercepts and an unstructured covariance
matrix were used to account for within-subject correl-
ation. Initial models included fixed effects for age at
baseline (centered at 70), education level (high school or
lower, college or higher), race (African-American vs. not
African-American), MIS version (version 1 vs. version
2), and annual visit, which was treated as acategorical
variable. Two-way interactions between visit and age,
race, and education were then added to the model.
Standard two-group comparisons (for example, t-tests
and chi-square (χ2) tests) were used to assess compar-
ability between the men who received alternating ver-
sions over four visits and those who received the same
version at baseline and first follow-up. Statistical signifi-
cance was set at α = 0.05. All analyses were performed
with SAS/STAT 9.3W software.
Results
Participants had an average ± SD baseline age of 68.0 ±
5.3 years and were highly educated, with 75.6% percent
reporting at least some college education (Table 1). Par-
ticipants with alternating MIS versions had received
similar levels of education to those given the same ver-
sion at baseline and follow-up but were slightly younger
(t = −2.18, degrees of freedom (df ) = 380.88, P = 0.03)
and comprised fewer minorities (χ2 = 33.4, df = 2, P <
0.0001). Almost half the men (47.0%) who received alter-
nating versions obtained a perfect score at baseline
(Table 2), and about half (49.8%) of those maintained
their perfect score at the first follow-up screen (data not
shown). Among men who did not achieve a perfect base-
line score (n = 955), 70.5% improved their score at the
first follow-up screen while just 6.0% performed worse.
Between baseline and follow-up visit 3, a 16.2% increase
in the proportion of men obtaining a perfect score was
observed along with corresponding decreases in the pro-
portion of men obtaining less than perfect scores
(McNemar’s χ2 = 5.5, df = 1, P = 0.02) (Table 2). By
Table 1 Baseline participant characteristics
Characteristics Alternating versions Same version
(n = 1,803) (n = 301)
Age, years, mean (SD) 67.8 (5.2) 68.6 (5.9)
Race, n (%)
African-American 133 (7.4) 27 (9.0)
White 1629 (90.4) 249 (82.7)
Other 41 (2.3) 25 (8.3)
Education level, n (%)
Unknown 8 (0.4) 0 (0.0)
High school or lower 447 (24.8) 63 (20.9)
Some college or higher 1348 (74.8) 238 (79.1)
Table 2 Memory Impairment Screen (MIS) scores by visit
All participants with alternating versions (n = 1,803)
Baseline
MIS
FU 1 MIS FU 2 MIS FU 3 MIS
MIS score, mean
(SD)
7.34 (0.74) 7.47 (0.68) 7.48 (0.70) 7.54 (0.69)
MIS score, n (%)
≤ 5 45 (2.5%) 24 (1.3%) 30 (1.7%) 33 (1.8%)
6 151 (8.4%) 123 (6.8%) 128 (7.1%) 103 (5.7%)
7 759 (42.1%) 632 (35.1%) 596 (33.1%) 527 (29.2%)
8 848 (47.0%) 1,024
(56.8%)
1,049
(58.2%)
1,140
(63.2%)
Total 1,803
(100%)
1,803
(100%)
1,803
(100%)
1,803
(100%)
Participants age 75 years or more at baseline with alternating
versions (n = 218)
Baseline
MIS
FU 1 MIS FU 2 MIS FU 3 MIS
MIS score, mean
(SD)
7.30 (0.81) 7.41 (0.71) 7.33 (0.76) 7.32 (0.82)
MIS score, n (%)
≤ 5 8 (3.7%) 2 (0.9%) 5 (2.3%) 10 (4.6%)
6 24 (11.0%) 22 (10.1%) 23 (10.6%) 19 (8.7%)
7 80 (36.7%) 79 (36.2%) 84 (38.5%) 80 (36.7%)
8 106 (48.6%) 115 (52.8%) 106 (48.6%) 109 (50.0%)
Total 218 (100%) 218 (100%) 218 (100%) 218 (100%)
FU, follow-up visit.
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contrast, although the same proportion of men (47.0%)
made a perfect score at baseline, a 14.0% increase in per-
fect scores was observed between baseline and follow-up
visit 1 among the men who received the same version at
the two assessments (McNemar’s χ2 = 10.9, df = 1, P =
0.001) (data not shown).
For the men with four visits and alternating MIS ver-
sions, all main effects except race were significant in the
initial LMM. Two-way interactions of age, education,
and version with visit were significant when added to
this model. A three-way interaction among age, educa-
tion, and visit was also tested and was not significant.
Hence, the final LMM contained random intercepts
(that is, subject effects); main effects for age, education,
visit, and MIS version; and visit by age, visit by educa-
tion, and visit by version interaction terms. The effects
of age and education in this model are illustrated in
Table 3. While there were few significant PE at the first
follow-up, which is unremarkable given almost half the
men already had a perfect score at baseline, the youngest
men (age 60 years) and men with the highest educa-
tional level did show a significant increase over baseline
and maintained this PE through the third follow-up. By
the second follow-up assessment a significant increase
over baseline, which was maintained at the third follow-
up, was observed for both educational levels and for all
men age 70 years or younger. Although their mean
scores did not decrease monotonically, men age 75 years
and older showed few significant PE and tended to have
lower estimated scores over time. Only the estimated
mean scores at follow-up visit 2 for men age 75 years
were significantly higher than baseline, while by follow-
up visit 3 men age 85 years had estimated mean scores
significantly lower than baseline. Finally, between base-
line and follow-up visit 3, the proportion of men age 75
years and older at baseline (n = 218) who achieved a
perfect score increased by just 1.4% in contrast to 70.5%
for the entire sample receiving alternate forms (Table 2).
Results changed little when men who obtained a per-
fect score at all four assessments were included in the
analysis. While there were no significant PE at follow-up
visit 1 for any age or educational level, PE were first
observed among the youngest and best educated partici-
pants, while the oldest participants (age 80 years or
more) had significantly lower estimated mean MIS
scores at the third follow-up than at baseline.
For the men who were given the same MIS version at
baseline and first follow-up (Table 4), only main effects for
age, education, version, and visit were significant predic-
tors of MIS score. For these men, there was a significant
improvement from baseline in the overall mean at the first
follow-up (0.20 ± 0.05 point increase, P = 0.0005), and this
holds true for even the oldest participants (0.17 ± 0.07
point increase, P = 0.02). Further, at follow-up visit 2,
where 75% of participants received the alternate version
for the first time, there was a non-significant decrease in
the overall mean (0.10 ± 0.06 points, P = 0.098), all of
which underscores the importance of alternating instru-
ment versions to minimize PE in screening. These men
were quite similar to those who received alternating ver-
sions of the MIS on all baseline characteristics except race,
which is likely due to MIS administration errors occurring
more often at certain study sites that happened to have
more non-white participants. Since race was not a signifi-
cant predictor in this analysis, however, the higher propor-
tion of African-Americans and other races in this group
does not explain the PE.
Discussion
Determining the success or failure of a dementia preven-
tion trial depends heavily on the ability of the investiga-
tors to ascertain caseness. In a large trial, where budget
Table 3 Adjusted mean Memory Impairment Screen (MIS) scores based on a linear mixed model (LMM): alternating
versions from baseline through follow-up (FU) visit 3 (n = 1,803)
LMM factor Baseline MIS FU 1 MIS FU 2 MIS FU 3 MIS
Education
≤ High school 7.29 (0.03) 7.28 (0.03) 7.45 (0.03)1,2 7.53 (0.03)1,2
≥ Some college 7.40 (0.02) 7.46 (0.02)1 7.53 (0.02)1,2 7.53 (0.02)1,3
Age, years
60 7.37 (0.03) 7.46 (0.03)1 7.61 (0.03)1,2 7.71 (0.03)1,2,3
65 7.36 (0.02) 7.41 (0.02) 7.53 (0.02)1,2 7.59 (0.02)1,2
70 7.34 (0.02) 7.35 (0.02) 7.46 (0.02)1,2 7.48 (0.02)1,2
75 7.33 (0.03) 7.29 (0.03) 7.38 (0.03)2 7.36 (0.03)
80 7.31 (0.04) 7.23 (0.04) 7.31 (0.04) 7.25 (0.04)
85 7.29 (0.06) 7.17 (0.06) 7.23 (0.06) 7.13 (0.06)4
Results are presented as mean score (SEM).1significantly higher than baseline; 2significantly higher than FU 1; 3significantly higher than FU 2; 4significantly lower
than baseline.
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and time constraints may dictate the use of uncompli-
cated screening instruments, unrecognized PE may mask
impairment and consequently bias results. In such cases
it is desirable to minimize PE to identify individuals who
need further evaluation.
We examined PE over four annual presentations of a
brief memory screen, the MIS. In contrast to several pre-
vious studies of other instruments, we found a robust PE
between the first and second presentation only when
identical test forms were used. Use of alternate versions
largely mitigated the PE at first follow-up, although PE
was observed for those with at least some college educa-
tion and for the youngest participants, which is consist-
ent with findings from other studies. Interestingly, there
were few PE for the oldest participants when alternate
forms were used consistently. In fact, similar to the find-
ings from the 5-year Personnes Agées QUID (PAQUID)
study [30], these participants tended to do worse over
time, which may support the hypothesis that a lack of
PE may signal early cognitive decline [8,31,32].
The study population consisted only of men, and there-
fore potential gender differences could not be studied,
therefore the generalizability of findings to women is un-
certain. Moreover, treatment effects of vitamin E and
selenium, if they exist, could not be assessed as the investi-
gators remain blinded to treatment arm. The utility of
these results is limited by the nature of the MIS, an
exclusively memory-based measure that neglects other
areas of cognitive functioning. In addition, because of the
restricted range and clear ceiling effect with this instru-
ment, men who had a perfect score could not improve;
the floor effect was not a factor since none of the partici-
pants in our study scored zero. However, the relatively
small mean increases in scores between visits reflect the
limited range of the MIS and should not be mistaken for
clinically insignificant changes. It is notable that PE of any
magnitude were found on a brief, four-item screening
measure with identical versions being presented two years
apart. Further, while the changes in the means were small,
the proportion of perfect scores increased steadily and
quite dramatically over time, if alternating versions were
not used. These results continue to support the use of al-
ternate forms in clinical and research settings where iden-
tifying candidates for further evaluation is the goal.
This study contributes to the literature in several ways.
First, it adds to the information on the variability of cog-
nitive screening measures across long periods of time,
especially for longitudinal aging trials. It also adds to the
information on the performance of the MIS as a brief
screening measure for participants of varying age, educa-
tion, and ethnic background. These data should further
serve to inform the design and implementation of future
dementia prevention studies.
Although there are several longitudinal studies investi-
gating reliable change indices (RCI), we view this as an
issue that is related to but separate from PE. More spe-
cifically, RCI allow one to control for the effect of prac-
tice in determining whether there has been a reliable
change in cognition over time. Screening measures used
in longitudinal studies are typically not used to detect
subtle declines per se but rather to re-screen participants
for inclusion into or exclusion from a study. Addition-
ally, some studies have shown that RCIs must be rather
large to reflect credible change [33-37]. However, a PE
of just one point can be consequential enough to have
detrimental effects on case ascertainment.
Conclusion
In this paper, we present the results of PE on a sample
of 2,104 cognitively intact adult men over age 60 years,
tested annually over four years. Strengths of the design
itself include the large sample size, longitudinal nature
of the study, and use of alternate forms for the vast ma-
jority of examinees. This study also demonstrates subtle
Table 4 Adjusted mean Memory Impairment Screen (MIS) scores based on a linear mixed model (LMM): same version
at baseline and follow-up (FU) visit 1 (n = 301)
LMM Factor Baseline MIS FU 1 MIS FU 2 MIS FU 3 MIS
Education
≤ High school 7.25 (0.05) 7.36 (0.09) 7.31 (0.09) 7.40 (0.10)
≥ Some college 7.35 (0.05) 7.57 (0.05)1 7.45 (0.05) 7.65 (0.05)1,2
Age, years
60 7.48 (0.07) 7.65 (0.07)1 7.57 (0.07) 7.71 (0.07)1
65 7.38 (0.06) 7.54 (0.06)1 7.46 (0.06) 7.60 (0.06)
70 7.27 (0.05) 7.43 (0.05)1 7.35 (0.06) 7.49 (0.05)1
75 7.16 (0.06) 7.32 (0.06)1 7.24 (0.06) 7.39 (0.06)1
80 7.05 (0.07) 7.22 (0.07)1 7.14 (0.07) 7.28 (0.07)1
85 6.94 (0.09) 7.11 (0.09)1 7.03 (0.09) 7.17 (0.09)1
Results are presented as mean score (SEM).1significantly higher than baseline; 2significantly higher than FU 2.
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but important shifts toward improved scores over time
on a brief screening measure. Given the importance of
repeated brief screening measures to clinical trial case
ascertainment, our study highlights the importance of
evaluating the effect of practice on specific instruments
used in longitudinal clinical trials. Future research may
wish to explore the possibility of adjusting cut-points on
repeated measures, and determining the effect this might
have on overall case ascertainment.
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